Clinical trials: Tace
Hepatocellular Carcinoma, Portal Vein Tumor Thrombosis
Transarterial Chemoembolization (TACE) With Radiation Therapy (RT) in Advanced Hepatocellular Carcinoma (HCC)
The presence of portal vein tumor thrombosis (PVTT) in patients with hepatocellular carcinoma (HCC) is one of the most significant prognostic factors for poor prognosis, without treatment, their survival is less than 3 months.
- Trial name
- NCT02290977
- Testing
- Scheduled interval TACE - RT
- Where
- South Korea
- Volunteers
- 40 people
- Sponsor
- Samsung Medical Center
Liver Neoplasms
Transarterial Chemoembolization Versus Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma
Rationale: This study will compare head to head in patients with hepatocellular carcinoma (HCC) ineligible for surgery or radiofrequency ablation, the standard treatment arm, transarterial chemoembolization with drug-eluting…
- Trial name
- TRENDY (NCT02470533)
- Testing
- Radiation therapy, chemoembolization
- Where
- 11 sites in Belgium, France and 1 more
- Volunteers
- 100 people
- Sponsor
- Erasmus Medical Center
Carcinoma, Hepatocellular
A Retrospective Study on the Treatment of Intermediate and Advanced Liver Cancer.
To evaluate the effectiveness of TACE combined with immunotherapy and targeted therapy versus TACE alone in patients with intermediate and advanced liver cancer.
- Trial name
- NCT06205732
- Testing
- Immunotherapy, targeted therapy.
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Qianfoshan Hospital
Hepatocellular Carcinoma (HCC), Immunotherapy
A Single-Arm, Multicenter, Exploratory Clinical Study of Transarterial Chemoembolization (TACE) Combined With Iparomlimab and Tuvonralimab Injection and Bevacizumab Injection for the Treatment of Unresectable, Non-Metastatic Hepatocellular Carcinoma (HCC)
This is a single-arm, multicenter, exploratory clinical study designed to evaluate the efficacy and safety of TACE combined with Iparomlimab and Tuvonralimab Injection and Bevacizumab Injection in patients with unresectable…
- Conditions
- Hepatocellular Carcinoma (HCC), Immunotherapy, PD-1, CTLA-4
- Trial name
- NCT07128251
- Testing
- TACE treatment, Iparomlimab and Tuvonralimab Injection (QL1706), Bevacizumab
- Volunteers
- 47 people
- Sponsor
- Anhui Provincial Hospital
Hepatocellular Carcinoma
Prognosis Stratification for Advanced HCC Receiving TACE with PD-1/PD-L1 Inhibitors and Molecular Target Therapies
The purpose of this study is to establish a personalized model of prognosis stratification for patients with advanced-stage hepatocellular carcinoma (HCC) receiving transarterial chemoembolization (TACE) in combination with…
- Trial name
- NCT06607120
- Where
- China
- Volunteers
- 950 people
- Sponsor
- Zhongda Hospital
Hepatocellular Carcinoma (HCC), Transarterial Chemoembolization
CECT Features of MVI Predict Response to TACE Plus TKI in Intermediate-stage HCC
This retrospective multicenter study aims to evaluate whether radiographic microvascular invasion (MVI) status can predict treatment response in patients with intermediate-stage hepatocellular carcinoma (HCC) receiving…
- Conditions
- Hepatocellular Carcinoma (HCC), Transarterial Chemoembolization, Microvascular Invasion (MVI), Tyrosine Kinase Inhibitors
- Trial name
- NCT07449065
- Testing
- TKI, TACE
- Where
- China
- Volunteers
- 324 people
- Sponsor
- First Affiliated Hospital, Sun Yat-Sen University
Hepatocellular Carcinoma
Toripalimab Plus Sorafenib in Patients With Advanced-Stage Hepatocellular Carcinoma
Toripalimab is a programmed cell death protein 1 antibody.This is an open-label, single arm, multi-center exploratory study.The objective of this study is to evaluate the efficacy and safety of therapy with toripalimab and…
- Trial name
- Toripalimab (NCT04926532)
- Testing
- Toripalimab, Sorafenib
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Shanghai Zhongshan Hospital
Hepatocellular Carcinoma
Evaluation Effectiveness and Safety of (cTACE or DEB-TACE + FOLFOX Regimen HAIC) Combined With Camrelizumab and Apatinib Mesylas in the Treatment of Advanced Hepatocellular Carcinoma
This study used (cTACE or DEB-TACE + FOLFOX scheme HAIC) combined with PD-1 antibody camrelizumab and apatinib mesylas in the treatment of patients with advanced liver cancer, to evaluate the effectiveness and safety of the…
- Trial name
- NCT04479527
- Testing
- Camrelizumab
- Volunteers
- 34 people
- Sponsor
- Peking University Cancer Hospital & Institute
Hepatocellular Carcinoma
HAIC Combined With Second-line "Target Immunity" for HCC With TACE Standard Treatment Low Response or Failure
This study is a prospective, randomized controlled, multicenter clinical study. The purpose of this study is to explore the efficacy and safety of hepatic artery infusion chemotherapy (HAIC) combined with second-line regorafenib…
- Trial name
- NCT05233358
- Testing
- Hepatic Artery Infusion Chemotherapy, Transarterial Chemoembolization, Regorafenib
- Volunteers
- 176 people
- Sponsor
- The Central Hospital of Lishui City
Advanced Hepatocellular Carcinoma
TACE Combined With PD-1 Knockout Engineered T Cell in Advanced Hepatocellular Carcinoma.
This study will evaluate the safety and effect of transcatheter arterial chemoembolization (TACE)combined with percutaneous transhepatic PD-1 knockout engineered T cell infusion in the Paitents with advanced hepatocellular…
- Trial name
- NCT04417764
- Testing
- Transcatheter arterial chemoembolization, PD-1 knockout engineered T cells
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Central South University
Hepatocellular Carcinoma, Immunotherapy
A Single-Arm, Multicenter, Exploratory Clinical Study of TACE Combined With Iparomlimab and Tuvonralimab Injection (QL1706) and Lenvatinib for Perioperative Treatment of Resectable Hepatocellular Carcinoma
This is a single-arm, multicenter, exploratory clinical study evaluating the efficacy and safety of TACE combined with Iparomlimab and Tuvonralimab Injection (QL1706) and lenvatinib for perioperative treatment of resectable HCC…
- Conditions
- Hepatocellular Carcinoma, Immunotherapy, Preoperative, PD-1
- Trial name
- NCT07131501
- Testing
- Radical surgery, TACE treatment, Iparomlimab and Tuvonralimab Injection (QL1706)
- Where
- China
- Volunteers
- 48 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Hepatocellular Carcinoma (HCC)
Outcome of Transarterial Chemo-embolization (TACE) in Hepatocellular Carcinoma Patients With Partial Portal Vein Thrombosis
Portal vein tumor invasion (PVT) is a common complication in HCC. the studyb Aimed to assess the outcomes after TACE in patients with branch PVT regarding Child classification, radiological response and 1 year survival.
- Trial name
- NCT03007212
- Testing
- transarterial chemoembolization versus the standard treatment with sorafinib
- Volunteers
- 30 people
- Sponsor
- Ain Shams University
Liver Cancer
Transarterial Chemoembolization Using Doxorubicin Beads With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery
RATIONALE: Drugs used in chemotherapy, such as doxorubicin, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT01324076
- Testing
- doxorubicin-eluting beads, sorafenib tosylate, laboratory biomarker analysis
- Where
- 8 sites in United Kingdom
- Volunteers
- 412 people
- Sponsor
- University College, London
HepatoCellular Carcinoma
HAIC Versus TACE for Large Hepatocellular Carcinoma Staged BCLC A/B.
The purpose of this study is to evaluate the efficacy and safety of hepatic arterial infusion chemotherapy (HAIC) compared with transarterial chemoembolization (TACE) in patients with large hepatocellular carcinoma staged BCLC…
- Trial name
- NCT02973685
- Testing
- Hepatic arterial infusion chemotherapy, Transarterial chemoembolization, Folfox Protocol
- Where
- 3 sites in China
- Volunteers
- 315 people
- Sponsor
- Sun Yat-sen University
Hepatocellular Carcinoma
Comparison Study of Transarterial Chemoembolization and Percutaneous Ethanol Injection for Multiple, Small HCCs
The purpose of this study is to choose the preferred treatment modality for multiple, small hepatocellular carcinomas.
- Trial name
- NCT00357474
- Testing
- Transarterial chemoembolization, Percutaneous ethanol injection therapy
- Where
- South Korea
- Volunteers
- 22 people
- Sponsor
- Seoul National University Hospital
Liver Cancer
HAIC + DEB-TACE + Toripalimab + Lenvatinib for Unresectable Intrahepatic Cholangiocarcinoma
Purpose: This phase II clinical trial evaluates whether a combination of liver-directed local therapies (HAIC and DEB-TACE) with immunotherapy (toripalimab) and targeted therapy (lenvatinib) is safe and effective for patients…
- Trial name
- NCT07685535
- Testing
- DEB-TACE, Toripalimab, Lenvatinib
- Volunteers
- 29 people
- Sponsor
- Shanghai Zhongshan Hospital
Advanced Hepatocellular Carcinoma (HCC)
The Comparison Between HepaSphere Drug-eluting Bead Transarterial Chemoembolization Combined With Hepatic Arterial Infusion Chemotherapy in Advanced Hepatocellular Carcinoma
Transarterial chemoembolization (TACE) is widely applied and shows good efficacy in advanced hepatocellular carcinoma (HCC). Recently, hepatic arterial infusion chemotherapy (HAIC) has also gained popularity in the treatment of…
- Trial name
- NCT05862181
- Testing
- DEB-TACE plus HAIC or HAIC alone
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Peking University Cancer Hospital & Institute
Hepatocellular Carcinoma
TACE With Dicycloplatin(TP21) in Unresectable HCC
To evaluate the effectiveness and safety of TP21 injection for TACE in treatment of hepatocellular carcinoma: 1. Primary efficacy endpoint: progression-free survival (PFS), which will be assessed by the Independent Review…
- Trial name
- NCT05472896
- Testing
- cTACE, Dicycloplatin (TP21), Epirubicin
- Where
- China
- Volunteers
- 332 people
- Sponsor
- Gao-jun Teng
Hepatocellular Carcinoma by BCLC Stage
TACE Combined With Bevacizumab in HCC (BCLC-B) Beyond Up-To-Seven Criteria
The purpose of this study is to evaluate the efficacy and safety of transcatheter arterial chemoembolization (TACE) combined with anti-VEGF (Bevacizumab Biosimilar) in patients with BCLC-B stage hepatocellular carcinoma beyond…
- Trial name
- B-TACE (NCT05883176)
- Testing
- Bevacizumab Biosimilar QL 1101
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Sun Yat-sen University
Hepatocellular Carcinoma, Atezolizumab Plus Bevacizumab
Low-Dose Bevacizumab and Atezolizumab Combined With TACE-HAIC in Unresectable Hepatocellular Carcinoma
This is a prospective, single-arm, phase II clinical study designed to evaluate the efficacy and safety of low-dose bevacizumab plus atezolizumab combined with transarterial chemoembolization followed by hepatic arterial infusion…
- Conditions
- Hepatocellular Carcinoma, Atezolizumab Plus Bevacizumab, Transarterial Chemoembolization
- Trial name
- NCT07543510
- Testing
- TACE-HAIC + Atezolizumab + Low-dose Bevacizumab
- Volunteers
- 38 people
- Sponsor
- Third Affiliated Hospital, Sun Yat-Sen University